OptiMATe Trial

This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival. Two arms are compared, in the experimental treatment group, participants receive one course of R/HD-MTX, followed by two courses of MATRix and autologous stem cell transplantation. In the control treatment, participants receive four coourses of MATRix followed by autologous stem cell transplantation.

• Studientyp: mulstizentrische Studie
• Tumorart: Leukämien und Lymphome
• Entität: ZNS Lymphome
• Standort:
  • Klinikum Stuttgart
  • E-Mail: scc-studienzentrale@klinikum-stuttgart.de
  • Tel.: 0711 278-30410
  • Website
• Rekrutierungsstatus: rekrutierend
• Alter: 18+
• Studienphase: Phase3
• Weitere Informationen